ProQR Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares Press release LEIDEN, The Netherlands, Sept. 23, 2014 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. September 23, 2014
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares Press release LEIDEN, the Netherlands and CAMBRIDGE, Mass., Oct. 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. October 18, 2019
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 11, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. September 11, 2018
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. April 05, 2021
Privacy Page This privacy statement informs our website visitors on what, for what purposes and how we process personal data.
ProQR founding story Page When our CEO, Daniel A. de Boer, knew his newborn son had an incurable rare disease, he founded ProQR to help people like his son. Learn more.
About ProQR Therapeutics Page An innovative biotech company advancing our proprietary Axiomer RNA-editing platform technology.
Presentations & Publications Page Find all relevant presentations and publications for each of our programs. From review papers to preclinical posters and clinical data presentations at medical conferences.
Partnerships Page ProQR has collaborations with important names in the industry including Eli Lilly and Company. Read more about our partnerships.